Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
venom desensitisation + Advax
- Development stage
- Unknown
- Lead developer
- Vaxine
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Venom desensitisation + Advax is an adjuvanted allergy immunotherapy vaccine being developed by Vaxine for the treatment of insect venom allergy, specifically targeting bee and ant venom. The formulation combines venom allergens with Vaxine's proprietary Advax adjuvant, which is based on delta-inulin. The mechanism of action involves inducing immune tolerance and stimulating the production of protective IgG blocking antibodies, which compete with IgE for allergen binding, thereby reducing the allergic response upon subsequent exposure to venom. It is currently in Phase 1 clinical development.
- Other names
- bee/ant venom allergy immunotherapyvenom immunotherapy + Advax
02
Targets
Myrmecia pilosula venom allergensHoney bee venom allergens
Beyond the preview
Go deeper on venom desensitisation + Advax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on venom desensitisation + Advax.